Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Jun 2026

Creech Lindsey, King William, Kleehammer Andrew Chase, Zuercher Hannah, Pittman Katarina, Miquel-Chambers Christopher, Piranio Vincent, Iakovidis Alexandria, Nguyen Khoa Anh, Qumseya Bashar J

Abstract excerpt

BACKGROUND & AIMS: Gastroesophageal reflux disease (GERD) is one of the most diagnosed diseases in the United States. A large proportion of patients have an inadequate response to proton pump inhibitors (PPIs), despite the optimization of dosing and timing. We hypothesized that such an inadequate response is often due to polymorphisms in cytochrome P450 2C19 (CYP2C19, CYP). This study aimed to assess the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gastroesophageal Reflux

Share to CYP2C19 gene

Share to Genotype

Share to Prevalence

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 41197932
DOI: 10.1016/j.cgh.2025.10.021

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.PMID 41197932Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Semantic proximity Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

CYP2C19 genetic polymorphisms and proton pump inhibitor therapy resistance in patients with gastrooesophageal reflux disease: a preliminary observational cohort study.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Association of CYP2C19 Phenotype on Historical Medication Prescribing for Gastroesophageal Reflux Disease.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.